Literature DB >> 17406451

Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain.

Donna M Wilcock1, Marcia N Gordon, Dave Morgan.   

Abstract

In the current protocol, we describe the Congo red staining method and a method for separately quantifying vascular and parenchymal amyloid deposits in brain tissue sections. Congo red staining detects amyloid deposits in brain tissue of amyloid precursor protein transgenic mice and human Alzheimer's tissue. It detects compacted amyloid in a beta-sheet secondary structure and labels amyloid in both the brain parenchyma (amyloid plaques) and blood vessels. Congophilic amyloid in blood vessels is called cerebral amyloid angiopathy (CAA). To date, analysis of CAA has largely used a severity rating scale, including both qualitative and quantitative characteristics. Here, we describe a simple method for quantifying total Congophilic staining and resolution of this staining into the parenchymal and vascular components based on morphological criteria. It is becoming increasingly important to separately quantify various components of the Alzheimer's pathology, given the advancement of amyloid-lowering therapies into clinical trials. The entire procedure for the Congo red staining can be performed at room temperature (20-25 degrees C) in a fume hood. The staining protocol should take 1 h 30 min including time for coverslipping slides. Time required for image analysis depends greatly on the number of samples being analyzed and the software being used. In our hands, 30 images can be collected per hour and quantified in a further 2 h.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17406451     DOI: 10.1038/nprot.2006.277

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  57 in total

1.  Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer's disease and multiple sclerosis.

Authors:  P Hemachandra Reddy; Maria Manczak; Wei Zhao; Kazuhiro Nakamura; Christopher Bebbington; Geoffrey Yarranton; Peizhong Mao
Journal:  J Neurochem       Date:  2009-10-14       Impact factor: 5.372

Review 2.  Neuroprotection by spice-derived nutraceuticals: you are what you eat!

Authors:  Ramaswamy Kannappan; Subash Chandra Gupta; Ji Hye Kim; Simone Reuter; Bharat Bhushan Aggarwal
Journal:  Mol Neurobiol       Date:  2011-03-01       Impact factor: 5.590

3.  Delivery of BACE1 siRNA mediated by TARBP-BTP fusion protein reduces β-amyloid deposits in a transgenic mouse model of Alzheimer's disease.

Authors:  Mohamed Mohamed Haroon; Kamal Saba; Venkata Harshavardhan Boddedda; Jerald Mahesh Kumar; Anant Bahadur Patel; Vijaya Gopal
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

4.  IKKβ deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology.

Authors:  Yang Liu; Xu Liu; Wenlin Hao; Yann Decker; Robert Schomburg; Livia Fülöp; Manolis Pasparakis; Michael D Menger; Klaus Fassbender
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

5.  Aqueous extract of lavender (Lavandula angustifolia) improves the spatial performance of a rat model of Alzheimer's disease.

Authors:  Masoud Soheili Kashani; Mostafa Rezaei Tavirani; Sayyed Alireza Talaei; Mahmoud Salami
Journal:  Neurosci Bull       Date:  2011-04       Impact factor: 5.203

6.  Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice.

Authors:  Barbara Biscaro; Olle Lindvall; Christoph Hock; Christine T Ekdahl; Roger M Nitsch
Journal:  J Neurosci       Date:  2009-11-11       Impact factor: 6.167

7.  Astrocytic gap junctional communication is reduced in amyloid-β-treated cultured astrocytes, but not in Alzheimer's disease transgenic mice.

Authors:  Nancy F Cruz; Kelly K Ball; Gerald A Dienel
Journal:  ASN Neuro       Date:  2010-08-17       Impact factor: 4.146

8.  Vascular amyloid alters astrocytic water and potassium channels in mouse models and humans with Alzheimer's disease.

Authors:  D M Wilcock; M P Vitek; C A Colton
Journal:  Neuroscience       Date:  2009-01-19       Impact factor: 3.590

9.  Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease.

Authors:  Maria Manczak; Peizhong Mao; Kazuhiro Nakamura; Christopher Bebbington; Byung Park; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2009-07-19       Impact factor: 6.150

10.  Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.

Authors:  Erica M Weekman; Tiffany L Sudduth; Carly N Caverly; Timothy J Kopper; Oliver W Phillips; Dave K Powell; Donna M Wilcock
Journal:  J Neurosci       Date:  2016-09-21       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.